申请人:Merck Sharp & Dohme Ltd.
公开号:US06187805B1
公开(公告)日:2001-02-13
Three classes of indole and indoline derivatives are disclosed as ligands selective for the 5-HT6 receptors, and hence of value in the treatment or prevention of CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression and anxiety. A particular class, 1-substituted-4-(&ohgr;-N,N-dialkyl-aminoalkyl)indoles, are claimed as novel compounds.
揭示了三类吲哚和吲哚啉衍生物作为选择性结合到5-HT6受体的配体,因此在治疗或预防中枢神经系统疾病方面具有价值,包括阿尔茨海默病、帕金森病、精神分裂症、抑郁症和焦虑症。其中一类称为1-取代-4-(&ohgr;-N,N-二烷基氨基烷基)吲哚,被称为新型化合物。